Press release
Animal Drug Compounding Market Estimated to Cross US$ 1,373.8 Mn by 2024
Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/animal-drug-compounding-market.asp
Greater unavailability of generic veterinary medicine in desired dosage forms for optimum efficiency is boosting the global demand for compounded animal drugs. In addition to this, re-emergence of animal drug compounding offers valuable benefits to the pet owners, not just manufacturers. Persistence Market Research predicts that the global market for animal drug compounding, which is presently valued at US$ 844.2 Mn, will expand at 6.3% CAGR to bring in revenues worth US$ 1,373.8 Mn by end of 2024. During this forecast period, the market’s growth will be favored by informed decisions taken by pet owners, higher level of veterinary care expected by them and lack of scientific evidence to report adverse effects of compounded animal drugs.
The report cites that the popularity of alternate flavored dosage forms will favor the adoption of animal drug compounding. Veterinary drug compounders try to remove the bitter taste of the medicine and make it feel non-gritty, smooth, creamy thus contributing largely towards improved patient compliance. The better the ability of a compounding pharmacist in creating flavored dosages, the greater are the future revenue-generating opportunities for manufacturers. Companies such as Triangle Compounding Pharmacy Inc., Lorraine’s Pharmacy, Medisca Inc., WEDGEWOOD PHARMACY, Diamondback Drugs LLC, ESSENTIAL PHARMACY COMPOUNDING VET (Kohll’s Pharmacy & Homecare), and Slade Dispensary Services are profiled in the report as key manufacturers of compounded animal drugs in the world.
Request to view table of content @ http://www.persistencemarketresearch.com/market-research/animal-drug-compounding-market/toc
Availability of accreditation also enhanced sales prospects of compounded animal drugs. In the event of adverse events not being recorded, animal owners generally prefer to visit only accredited compounding pharmacies. In addition to this, lower availability of generic substitutes to veterinary drugs also propels the practice of compounding veterinary pharmaceuticals. Currently there is no reimbursement available for veterinary drugs, which indicate most of the drug expense goes out of pockets of animal owners. In such circumstances, most animal owners prefer resorting to compounded animal medications that are easily available, cheaper than branded equivalents and do not require multiple prescriptions.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/12871
Global Animal Drug Compounding Market – Top Report Excerpts
In the due course of forecast period, the global animal drug compounding market will witness impressive growth for products namely, CNS agents, anti-infective agents, and hormonal drugs, While CNS agents will account for over 37% share of global revenues, global sales of anti-infective agents will record revenue growth at 7.8% CAGR, Companion animals will account for 47% of global animal drug compounding revenues throughout the forecast period, and dogs will be procuring highest usage of compounded drugs for companion animals, More than half of the market’s worth will be accounted by sales of compounded drugs for livestock animals, but their market presence will incur a decline towards the end of 2024, Through 2024, more than 80% of the global animal drug compounding market value will be attributed by orally-formulated drugs
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Animal Drug Compounding Market Estimated to Cross US$ 1,373.8 Mn by 2024 here
News-ID: 571412 • Views: …
More Releases from Persistence Market Research PVT. LTD.
Battery Material Market is projected to reach a valuation of US$ 110.02 billion …
The battery material market has witnessed significant growth in recent years, driven by the increasing demand for batteries in various applications. According to recent studies, the market was valued at USD 42.1 billion in 2022 and is projected to reach USD 110.02 billion by 2027, growing at a CAGR of 14.1% during the forecast period.
Click Here to Get Free Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/10801
The battery material market encompasses a wide…
Automated Intralogistics Material Handling Solutions Market to Hit US$ 219.3 b …
Automated intralogistics material handling solution sales are anticipated to achieve a global market value of US$ 55.9 billion in 2023 and to grow steadily at a CAGR of 14.8% to reach US$ 219.3 billion by 2033.
The global intralogistics material handling solutions market is experiencing a revolution with the introduction of automated systems. Automation has become a game-changer, offering greater efficiency and productivity to businesses across the globe. The market for automated intralogistics material handling solutions is projected to witness impressive growth in the coming years.
Click Here to Get Free Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/32829
The key drivers for the growth of the automated intralogistics material handling…
Cold Chain Market is Encouraged to Reach USD 474.29 billion by 2028
The global cold chain market size was valued at USD 211.77 billion in 2020 and is expected to reach USD 474.29 billion by 2028, growing at a CAGR of 9.7% from 2021 to 2028. The growth is driven by increasing demand for perishable goods, globalization of the food trade, and technological advancements in cold chain logistics.
Click Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/3177
The cold chain market refers…
Automated Intralogistics Material Handling Solutions Market Value to Hit US$ 219 …
𝐀𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐈𝐧𝐭𝐫𝐚𝐥𝐨𝐠𝐢𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐭𝐞𝐫𝐢𝐚𝐥 𝐇𝐚𝐧𝐝𝐥𝐢𝐧𝐠 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐌𝐚𝐫𝐤𝐞𝐭
𝐈𝐧 𝟐𝟎𝟐𝟑, 𝐬𝐚𝐥𝐞𝐬 𝐨𝐟 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐢𝐧𝐭𝐫𝐚𝐥𝐨𝐠𝐢𝐬𝐭𝐢𝐜𝐬 𝐦𝐚𝐭𝐞𝐫𝐢𝐚𝐥 𝐡𝐚𝐧𝐝𝐥𝐢𝐧𝐠 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐠𝐥𝐨𝐛𝐚𝐥 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒$ 𝟓𝟓.𝟗 𝐁𝐧 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐞𝐱𝐩𝐚𝐧𝐝 𝐬𝐭𝐞𝐚𝐝𝐢𝐥𝐲 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟒.𝟖% 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐚 𝐦𝐚𝐫𝐤𝐞𝐭 𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐥𝐨𝐬𝐞 𝐭𝐨 𝐔𝐒$ 𝟐𝟏𝟗.𝟑 𝐁𝐧 𝐛𝐲 𝟐𝟎𝟑𝟑.
The demand in Germany is expected to increase by 15.7% CAGR from 2024 to 2033 on a value basis. U.S., China, and Germany are the leading countries in the…
More Releases for Drug
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Indispensable Advent of Microcapsules
1.1 Trajectory of Microencapsulation
1.2 Why and wherefores for Microencapsulation
2. Characterization of Microcapsules
2.1 Composition of Microcapsules
2.2 Parameters Influencing Microcapsules
3. Engineering Technology of Microcapsules
3.1 Physical Manufacturing Technologies
3.2 Physicochemical and Chemical Technologies
4. Applicability of Microcapsules
4.1 Microcapsules in Pharmaceuticals
4.2 Microcapsules in Nutraceuticals
…
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug
European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning…
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June.
The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug…
